Switch to:

Arrowhead Pharmaceuticals Debt-to-EBITDA

: -0.37 As of Jun. 2020
View and export this data going back to 1997. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arrowhead Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $1.0 Mil. Arrowhead Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $20.4 Mil. Arrowhead Pharmaceuticals's annualized EBITDA for the quarter that ended in Jun. 2020 was $-57.6 Mil. Arrowhead Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2020 was -0.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NAS:ARWR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.76   Med: -0.06   Max: -0.01
Current: -0.76

-0.76
-0.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Arrowhead Pharmaceuticals was -0.01. The lowest was -0.76. And the median was -0.06.

NAS:ARWR's Debt-to-EBITDA is ranked lower than
99.99% of the 222 Companies
in the Biotechnology industry.

( Industry Median: 1.24 vs. NAS:ARWR: -0.76 )

Arrowhead Pharmaceuticals Debt-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Arrowhead Pharmaceuticals Annual Data
Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.04 -0.08 -0.05 0.00

Arrowhead Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.03 -0.18 -0.37

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Arrowhead Pharmaceuticals Debt-to-EBITDA Distribution

* The bar in red indicates where Arrowhead Pharmaceuticals's Debt-to-EBITDA falls into.



Arrowhead Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arrowhead Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Sep. 2019 is calculated as

Arrowhead Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.012 + 20.36) / -57.636
=-0.37

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2020) EBITDA data.


Arrowhead Pharmaceuticals  (NAS:ARWR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Arrowhead Pharmaceuticals Debt-to-EBITDA Related Terms


Arrowhead Pharmaceuticals Debt-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)